Rx Stocks Suffer Medicare Hangover; Aventis Bid Fails To Spark Rally

Aventis is winning the battle to persuade investors that it is worth more than Sanofi says, but the budding bidding war for the company has not been enough to cure Wall Street's aversion to pharmaceutical stocks